Abstract
Advances in early reperfusion therapies focused on the revascularization of the ischemic tissues, in the last decades, lead to reduced mortality in acute myocardial infarction (MI) patients. However, a large proportion of patients show inadequate myocardial perfusion because of dysfunction of the microcirculation. The high prevalence of microvascular dysfunction after reperfusion therapies and the negative prognostic of this procedure justify the search for therapeutic strategies that aim to restore the microvascular network. It is well known that the size of the initial infarct, the duration of ischemia and the efficiency of reperfusion determine myocardial tissue damage and cardiomyocyte loss after myocardial infarction. Therefore any advancement on the mechanisms that induce the repair process of microvascular dysfunction after reperfused MI is of great interest. Here, we will review the different proteins and cells known to participate in angiogenesis induction post-MI and we will also discuss the potential pharmacological and cellular processes that promote the recovery of microvasculature by angiogenesis stimulation after MI.
Keywords: Angiogenesis, reperfusion therapies, microvascular dysfunction, myocardial infarction, myocardial perfusion, ischemia.
Current Pharmaceutical Design
Title:Microvasculature Recovery by Angiogenesis After Myocardial Infarction
Volume: 24 Issue: 25
Author(s): Lina Badimon and Maria Borrell*
Affiliation:
- CIBER-CV, Instituto de Salud Carlos III, Madrid,Spain
Keywords: Angiogenesis, reperfusion therapies, microvascular dysfunction, myocardial infarction, myocardial perfusion, ischemia.
Abstract: Advances in early reperfusion therapies focused on the revascularization of the ischemic tissues, in the last decades, lead to reduced mortality in acute myocardial infarction (MI) patients. However, a large proportion of patients show inadequate myocardial perfusion because of dysfunction of the microcirculation. The high prevalence of microvascular dysfunction after reperfusion therapies and the negative prognostic of this procedure justify the search for therapeutic strategies that aim to restore the microvascular network. It is well known that the size of the initial infarct, the duration of ischemia and the efficiency of reperfusion determine myocardial tissue damage and cardiomyocyte loss after myocardial infarction. Therefore any advancement on the mechanisms that induce the repair process of microvascular dysfunction after reperfused MI is of great interest. Here, we will review the different proteins and cells known to participate in angiogenesis induction post-MI and we will also discuss the potential pharmacological and cellular processes that promote the recovery of microvasculature by angiogenesis stimulation after MI.
Export Options
About this article
Cite this article as:
Badimon Lina and Borrell Maria *, Microvasculature Recovery by Angiogenesis After Myocardial Infarction, Current Pharmaceutical Design 2018; 24 (25) . https://dx.doi.org/10.2174/1381612824666180629162726
DOI https://dx.doi.org/10.2174/1381612824666180629162726 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Chest Pain in Children
Current Pediatric Reviews LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Glibenclamide Action on Myocardial Function and Arrhythmia Incidence in the Healthy and Diabetic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Anti-Aging Drugs – Prospect of Longer Life?
Current Medicinal Chemistry Emerging Strategies and Agents to Lower Cardiovascular Risk by Increasing High Density Lipoprotein Cholesterol Levels
Current Medicinal Chemistry Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Combinatorial Therapies for Cardiac Regeneration
Recent Patents on Regenerative Medicine The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy
Current Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin
Current Pharmaceutical Design The Mode of Action of the Antidiabetic Drug Glimepiride-Beyond Insulin Secretion
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Editorial (Hot Topic: Vascular Remodeling)
Current Vascular Pharmacology Atherosclerotic Plaque Biomarkers: Beyond the Horizon of the Vulnerable Plaque
Current Cardiology Reviews